167 related articles for article (PubMed ID: 14560161)
1. Mistaken identity: misclassification of TPMT phenotype following blood transfusion.
Cheung ST; Allan RN
Eur J Gastroenterol Hepatol; 2003 Nov; 15(11):1245-7. PubMed ID: 14560161
[TBL] [Abstract][Full Text] [Related]
2. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM
Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981
[TBL] [Abstract][Full Text] [Related]
3. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription.
Fargher EA; Tricker K; Newman W; Elliott R; Roberts SA; Shaffer JL; Bruce I; Payne K
J Clin Pharm Ther; 2007 Apr; 32(2):187-95. PubMed ID: 17381669
[TBL] [Abstract][Full Text] [Related]
4. Normal thiopurine methyltransferase phenotype testing in a Crohn disease patient with azathioprine induced myelosuppression.
Leung M; Piatkov I; Rochester C; Boyages SC; Leong RW
Intern Med J; 2009 Feb; 39(2):121-6. PubMed ID: 19356188
[TBL] [Abstract][Full Text] [Related]
5. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?
Sanderson J; Ansari A; Marinaki T; Duley J
Ann Clin Biochem; 2004 Jul; 41(Pt 4):294-302. PubMed ID: 15298741
[TBL] [Abstract][Full Text] [Related]
6. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.
Gisbert JP; Niño P; Rodrigo L; Cara C; Guijarro LG
Am J Gastroenterol; 2006 Dec; 101(12):2769-76. PubMed ID: 17026564
[TBL] [Abstract][Full Text] [Related]
7. Azathioprine-induced fatal myelosuppression in systemic lupus erythematosus patient carrying TPMT*3C polymorphism.
Boonsrirat U; Angsuthum S; Vannaprasaht S; Kongpunvijit J; Hirankarn N; Tassaneeyakul W; Avihingsanon Y
Lupus; 2008 Feb; 17(2):132-4. PubMed ID: 18250137
[TBL] [Abstract][Full Text] [Related]
8. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis.
Hibi T; Naganuma M; Kitahora T; Kinjyo F; Shimoyama T
J Gastroenterol; 2003; 38(8):740-6. PubMed ID: 14505127
[TBL] [Abstract][Full Text] [Related]
9. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease.
Winter JW; Gaffney D; Shapiro D; Spooner RJ; Marinaki AM; Sanderson JD; Mills PR
Aliment Pharmacol Ther; 2007 May; 25(9):1069-77. PubMed ID: 17439508
[TBL] [Abstract][Full Text] [Related]
10. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients.
Snow JL; Gibson LE
Arch Dermatol; 1995 Feb; 131(2):193-7. PubMed ID: 7857117
[TBL] [Abstract][Full Text] [Related]
11. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case.
Tavadia SM; Mydlarski PR; Reis MD; Mittmann N; Pinkerton PH; Shear N; Sauder DN
J Am Acad Dermatol; 2000 Apr; 42(4):628-32. PubMed ID: 10727309
[TBL] [Abstract][Full Text] [Related]
12. Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine.
Clunie GP; Lennard L
Rheumatology (Oxford); 2004 Jan; 43(1):13-8. PubMed ID: 14566029
[TBL] [Abstract][Full Text] [Related]
13. Role of thiopurine methyltransferase activity in the safety and efficacy of azathioprine in the treatment of pemphigus vulgaris.
Firooz A; Ghandi N; Hallaji Z; Chams-Davatchi C; Valikhani M; Karbakhsh Davari M
Arch Dermatol; 2008 Sep; 144(9):1143-7. PubMed ID: 18794458
[TBL] [Abstract][Full Text] [Related]
14. An audit of thiopurine methyltransferase genotyping and phenotyping before intended azathioprine treatment for dermatological conditions.
Vestergaard T; Bygum A
Clin Exp Dermatol; 2010 Mar; 35(2):140-4. PubMed ID: 19663853
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of polymorphism and low activity of thiopurine methyltransferase in patients with inflammatory bowel disease.
Larussa T; Suraci E; Lentini M; Nazionale I; Gallo L; Abenavoli L; Imeneo M; Costanzo FS; Cuda G; Luzza F
Eur J Intern Med; 2012 Apr; 23(3):273-7. PubMed ID: 22385887
[TBL] [Abstract][Full Text] [Related]
16. Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center.
Banerjee S; Bishop WP
J Pediatr Gastroenterol Nutr; 2006 Sep; 43(3):324-30. PubMed ID: 16954954
[TBL] [Abstract][Full Text] [Related]
17. TPMT genotype and its clinical implication in renal transplant recipients with azathioprine treatment.
Song DK; Zhao J; Zhang LR
J Clin Pharm Ther; 2006 Dec; 31(6):627-35. PubMed ID: 17176368
[TBL] [Abstract][Full Text] [Related]
18. Paradoxical elevated thiopurine S-methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age.
de Boer NK; van Bodegraven AA; de Graaf P; van der Hulst RW; Zoetekouw L; van Kuilenburg AB
Ther Drug Monit; 2008 Jun; 30(3):390-3. PubMed ID: 18520612
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
[TBL] [Abstract][Full Text] [Related]
20. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
